Scholarlink

<p>Since the identification of SARS-CoV-2 in late 2019, the continuous evolution of viral variants has represented a challenge to vaccination efforts worldwide. The recent emergence of Omicron viral sublineages has urged the need for updated vaccine formulations in order to maintain efficacy, especially among high-risk populations who are susceptible to severe COVID-19 manifestations. This review aims to comprehend how COVID-19 vaccination strategies evolved and to accentuate FDA-approved vaccines for the 2025–2026 season. The 2025–2026 FDA-approved vaccines- Pfizer-BioNTech’s Comirnaty<sup>®</sup> LP.8.1, Moderna’s Spikevax LP.8.1 (and mNEXSPIKE), and Novavax’s Nuvaxovid LP.8.1-target the JN.1 variant and elicit strong neutralising antibody responses. Real-world results suggest a relatively low risk of hospitalisation and mortality connected to COVID-19 among persons aged 65 years and older. Safety profiles were consistent with previous formulations, and no new safety concerns were noted. Economic models further add to the cost-effectiveness of vaccination in lowering hospitalisations and healthcare burden in high-risk groups. COVID-19 Vaccinations updated for the 2025–2026 season are highly immunogenic and well protective against severe COVID manifestations in a high-risk cohort. Targeted vaccination strategies, tuned to the variants’ changing dynamics, are required to diminish COVID-19’s global impact while ensuring equity in protection for the most vulnerable population segments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adapting covid-19 vaccination through targeted approaches: FDA-approved vaccines for the 2025–2026 season

  • 期刊论文

  • 发表日期：

    2026年3月14日

查看全文
  • Rukaiah Fatma Begum,
  • Midhun Mathew,
  • Pratik Prashant Doshi,
  • Swathi Suresh

摘要

Since the identification of SARS-CoV-2 in late 2019, the continuous evolution of viral variants has represented a challenge to vaccination efforts worldwide. The recent emergence of Omicron viral sublineages has urged the need for updated vaccine formulations in order to maintain efficacy, especially among high-risk populations who are susceptible to severe COVID-19 manifestations. This review aims to comprehend how COVID-19 vaccination strategies evolved and to accentuate FDA-approved vaccines for the 2025–2026 season. The 2025–2026 FDA-approved vaccines- Pfizer-BioNTech’s Comirnaty® LP.8.1, Moderna’s Spikevax LP.8.1 (and mNEXSPIKE), and Novavax’s Nuvaxovid LP.8.1-target the JN.1 variant and elicit strong neutralising antibody responses. Real-world results suggest a relatively low risk of hospitalisation and mortality connected to COVID-19 among persons aged 65 years and older. Safety profiles were consistent with previous formulations, and no new safety concerns were noted. Economic models further add to the cost-effectiveness of vaccination in lowering hospitalisations and healthcare burden in high-risk groups. COVID-19 Vaccinations updated for the 2025–2026 season are highly immunogenic and well protective against severe COVID manifestations in a high-risk cohort. Targeted vaccination strategies, tuned to the variants’ changing dynamics, are required to diminish COVID-19’s global impact while ensuring equity in protection for the most vulnerable population segments.